prnewswire
Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
VALBY, Denmark, July 23, 2026 /PRNewswire/ -- Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 receptor agonist and one of several investigational compounds in Lundbeck's development portfoli…